Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
196 studies found for:    "Poliomyelitis"
Show Display Options
Rank Status Study
21 Completed 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants
Condition: Poliomyelitis
Interventions: Biological: Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI;   Biological: IPV Vaccine SSI
22 Completed Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine
Condition: Poliomyelitis
Intervention: Biological: poliovirus vaccine
23 Completed Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults
Condition: Poliomyelitis
Interventions: Drug: IPV;   Drug: Sabin-IPV;   Drug: Adjuvanted Sabin-IPV
24 Completed Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV
Conditions: Poliomyelitis;   Polio
Interventions: Biological: Poliomyelitis Vaccine inactivated;   Biological: Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)
25 Recruiting Safety and Immunogenicity of IPOVAC in Young Children
Condition: Poliomyelitis
Interventions: Biological: IMOVAC-POLIO;   Biological: IPOVAC 1.5:5:5;   Biological: IPOVAC, 3:10:10;   Biological: IPOVAC, 6:20:20
26 Completed Polio NID and Routine EPI Integration Trial Pakistan
Condition: Polio
Interventions: Behavioral: Vaccine promotion messages;   Other: Vaccination Verification.;   Other: Distribution of Plastic Pouches to retain vaccination card
27 Completed Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules
Condition: Poliomyelitis
Interventions: Biological: bOPV (three dose);   Biological: bOPV (two dose);   Biological: IPV
28 Completed A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
Condition: Poliomyelitis
Intervention: Biological: Poliomyelitis vaccine (inactivated) -PoliorixTM
29 Not yet recruiting IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults
Condition: Poliomyelitis
Interventions: Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV);   Biological: Reference IPV;   Biological: sIPV Placebo
30 Completed Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine
Condition: Poliomyelitis
Interventions: Biological: Bivalent Oral Polio Vaccine (bOPV);   Biological: Trivalent Oral Polio Vaccine (tOPV);   Biological: Monovalent Oral Polio Vaccine Type 2 (mOPV2);   Biological: Sanofi-Pasteur IPV (Sanofi IPV);   Biological: Glaxo SmithKline IPV (GSK IPV);   Biological: Serum Institute of India IPV (SII IPV)
31 Enrolling by invitation Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine
Condition: Poliomyelitis
Interventions: Biological: IPV;   Biological: OPV
32 Unknown  Study of Mental Fatigue in Polio Survivors
Condition: Post-Poliomyelitis Syndrome
Intervention:
33 Not yet recruiting A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania
Condition: Poliomyelitis
Intervention: Biological: Sabin mOPV2
34 Not yet recruiting A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age
Condition: Poliomyelitis
Intervention: Biological: Oral Polio Vaccine
35 Completed
Has Results
Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
Condition: Polio Immunity
Intervention: Drug: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
36 Completed Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults
Condition: Poliomyelitis
Interventions: Biological: a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD);   Biological: a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).
37 Completed Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers
Condition: Poliomyelitis
Intervention: Biological: PoliorixTM
38 Completed Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants
Condition: Poliomyelitis
Interventions: Drug: IPV;   Drug: Low dose Sabin-IPV;   Drug: Low dose adjuvanted Sabin-IPV;   Drug: Middle dose Sabin-IPV;   Drug: Middle dose adjuvanted Sabin-IPV;   Drug: High dose Sabin-IPV;   Drug: High dose adjuvanted Sabin-IPV
39 Completed Study of "Post-Polio Syndrome"
Conditions: Poliomyelitis;   Postpoliomyelitis Syndrome
Intervention:
40 Active, not recruiting L-Citrulline in Patients With Post-Polio Syndrome
Condition: Post-Polio Syndrome
Interventions: Drug: 15g L-citrulline daily p.o.;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.